Cannabinoids reduce inflammation in a number of preclinical models of disease, including arthritis [83], multiple sclerosis (MS) [84, 85], inflammatory bowel disease (IBD) [86,87,88,89] and type 1 diabetes (T1D) [90,91,92,93]
This has the additional advantage of reducing body weight by reducing percentage fat in the body
The European Medicine Agency (EMA) approved daily liraglutide (3.0 mg) and weekly semaglutide (1.7 or 2.4 mg) for this indication in 2021
Intestinal Obstruction: There are reports linking Ozempic to blockages in the intestines, a potentially life-threatening condition, highlighting concerns about the drugs effects on gut motility and safety
FAQ What is the most common concentration for compounded semaglutide
Clinical trials indicate that Tirzepatide demonstrates greater effectiveness in lowering blood sugar and promoting weight loss compared to semaglutide